MedTrace Logo

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

NCT00766324 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2014-05-28

No results posted yet for this study

Summary

To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard, docetaxel-based 1st-line chemotherapy for HRPC based on PSA response, and to select the best dose schedule for further investigation.

Conditions

  • Metastatic Hormone Refractory Prostate Cancer

Interventions

DRUG

PHA-739358

6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle

DRUG

PHA-739358

24-hr IV infusion every 2 weeks in a 4-week cycle

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766324 on ClinicalTrials.gov